Erasca closed an upsized public offering, selling 25,875,000 shares at $10.00 each and generating approximately $258.8 million in gross proceeds. The company said all shares were sold by Erasca and that the underwriters exercised their full option, reflecting strong demand for financing among clinical‑stage precision oncology firms. The raise provides Erasca with near‑term capital to advance its RAS/MAPK pathway programs and ongoing clinical activities. Investors should watch how the company allocates proceeds between clinical development, biomarker strategies, and potential partnering or M&A moves.